<div><div></div><div><span><p><span>Aditxt, Inc. reported first-quarter 2026 results showing revenue of $12.16K, a wider net loss of ($15.95M) and diluted EPS of ($790.49) versus the prior-year quarter, reflecting growth in sales tied to the Ignite acquisition alongside increased operating costs related to development and integration activities.</span></p><p><strong><span>Financial Highlights</span></strong></p><div><table><tbody><tr><td><span>Metric</span></td><td><span>Current quarter</span></td><td><span>Prior year quarter</span></td><td><span>YoY change</span></td></tr><tr><td><span>Revenue¹</span></td><td><span>$12.16K</span></td><td><span>$1.02K</span></td><td><span>1094.4%</span></td></tr><tr><td><span>Net income²</span></td><td><span>($15.95M)</span></td><td><span>($5.71M)</span></td><td><span>(179.3%)</span></td></tr><tr><td><span>Diluted EPS³</span></td><td><span>($790.49)</span></td><td><span>($198072.98)</span></td><td><span>99.6%</span></td></tr></tbody></table></div><p><em><span>¹ Reported as “Sales”. ² Reported as “Net Loss Attributable To Aditxt, Inc. &amp; Subsidiaries”. ³ Reported as “loss per share, basic and diluted”.</span></em></p><p><strong><span>Business Highlights</span></strong></p><ul><li><span>Revenue growth to $12.2K in Q1 2026 from $1.0K in Q1 2025 was driven by the Ignite acquisition.</span></li><li><span>Completed ADI-100 preclinical studies and GMP manufacturing of clinical‑grade drug substance in preparation for IND submissions.</span></li><li><span>Pearsanta acquisition added Mitomic® and Adductomics assets; development continues on MPT™ and MET™ blood-based tests and build-out of CLIA laboratory capacity.</span></li><li><span>Clinical and partnership progress includes CRO engagement in Germany and collaboration with Mayo Clinic to support IND and planned SPS trial enrollment in 2026.</span></li></ul><p><span>Original SEC Filing: </span>Aditxt, Inc. [ ADTX ] - 10-Q - May. 20, 2026</p><section><b><span class="heading-JaE7wgR2">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

ADTX

IBBQ

SBIO

LABU

<p>Aditxt, Inc. reported Q1 2026 results with revenue of $12.16K, a net loss of $15.95M, and diluted EPS of ($790.49), reflecting significant growth from the Ignite acquisition but increased operating costs. Revenue rose 1094.4% year-over-year. The company completed preclinical studies and expanded its laboratory capacity, while also engaging in partnerships to support future clinical trials.</p>

TradingView

Aditxt

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Aditxt, Inc. 1Q 2026: Revenue $12.16K, Net income ($15.95M), EPS ($790.49) — 10-Q Summary